The U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) announced the allocation plan for the drug remdesivir. The allocation is from a donation by Gilead Sciences, Inc. to the United States which was finalized on May 3, 2020. The donated doses of the treatment, which received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration, will be used to treat hospitalized COVID-19 patients in areas of the country hardest hit by the pandemic.
You can read the press release from HHS here.
